1 terminated, 1 withdrawn. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 1, Withdrawn 1 |
Follow pralsetinib: new trials by email Literature Review of pralsetinib trials Research Report on pralsetinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). Pralsetinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer | Phase 3 | Withdrawn | Hoffmann-La Roche | 2023-11-30 | 2024-01-05 | |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Pralsetinib, Carboplatin, Cisplatin - RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm | Phase 3 | Terminated | Hoffmann-La Roche | 223 | 2020-07-24 | 2026-03-05 |
Adenocarcinoma (1) · Bronchial Diseases (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Medullary (1) · Carcinoma, Non-Small-Cell Lung (1) · Head and Neck Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Respiratory Tract Diseases (1)
Spain (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Costa Rica (1) · France (1) · Germany (1) · Ireland (1) · Italy (1) · Japan (1) · Mexico (1) · Netherlands (1) · Norway (1) · Panama (1)
2019 (1), 2023 (1)